{"url_path":"/sec/dcoy/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1615219/0001193125-26-214816-index.html","accession_number":"0001193125-26-214816","cik":"0001615219","ticker":"DCOY","issuer_name":"Decoy Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1615219/0001193125-26-214816-index.html","primary_entity_key":"0001615219","primary_entity_name":"Decoy Therapeutics Inc."},"word_count":737,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n \n\nExhibit\n\nnumber\n\nDescription of Document\n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on February 9, 2015](https://www.sec.gov/Archives/edgar/data/1615219/000110465915007801/a15-4061_1ex3d1.htm)\n\n3.2\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant filed with the Secretary of State of Delaware on July 18, 2019, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on July 22, 2019](https://www.sec.gov/Archives/edgar/data/1615219/000119312519199074/d754556dex31.htm)\n\n3.3\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware on October 14, 2022, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on October 14, 2022](https://www.sec.gov/Archives/edgar/data/1615219/000161521922000135/exhibit31.htm)\n\n3.4\n\n \n\n[Amended and Restated Bylaws of the Registrant, effective July 19, 2019, incorporated by reference to Exhibit 3.2 of the Form 8-K filed on July 22, 2019](https://www.sec.gov/Archives/edgar/data/1615219/000119312519199074/d754556dex32.htm)\n\n3.5\n\n \n\n[Amendment to Amended and Restated Bylaws of the Registrant, effective April 1, 2022, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on April 1, 2022](https://www.sec.gov/Archives/edgar/data/1615219/000161521922000034/salarius-bylawsamendment33.htm)\n\n3.6\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Salarius Pharmaceuticals, Inc., effective June 14, 2024, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on June 14, 2024](https://www.sec.gov/Archives/edgar/data/1615219/000161521924000045/slrx-certificateofamendm.htm)\n\n3.7\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Salarius Pharmaceuticals, Inc., effective August 15, 2025 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 15, 2025)](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000101/slrx-reversestocksplitamen.htm)\n\n3.8\n\n \n\n[Form of Certificate of Designation of Series A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 2.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 18, 2025)](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000135/certificateofdesignations-a.htm)\n\n3.9\n\n \n\n[Form of Certificate of Designation of Series B Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 2.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 18, 2025).](https://www.sec.gov/Archives/edgar/data/1615219/000161521925000135/certificateofdesignations-.htm)\n\n3.12\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Salarius Pharmaceuticals, Inc., effective January 8, 2026 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 8, 2026).](https://www.sec.gov/Archives/edgar/data/1615219/000161521926000013/exhibit31-delawarecertific.htm)\n\n3.13\n\n \n\n[Second Amended and Restated Bylaws of the Registrant, effective January 8, 2026 (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 8, 2026)](https://www.sec.gov/Archives/edgar/data/1615219/000161521926000013/exhibit32-secondamendedres.htm)\n\n3.14\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Decoy Therapeutics Inc., effective March 6, 2026 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on March 5, 2026).](https://www.sec.gov/Archives/edgar/data/1615219/000119312526092748/dcoy-ex3_1.htm)\n\n31.1\n\n \n\n[Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934](dcoy-ex31_1.htm)\n\n31.2\n\n \n\n[Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934](dcoy-ex31_2.htm)\n\n32.1*\n\n \n\n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350](dcoy-ex32_1.htm)\n\n101.0\n\n \n\nThe following materials from Salarius Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in XBRL (eXtensible Business Reporting Language):(i) Unaudited Condensed Consolidated Balance Sheets, (ii) Unaudited Condensed Consolidated Statements of Operations (iii) Unaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit), (iv) Unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Unaudited Consolidated Financial Statements.\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the inline XBRL document and included in Exhibit 101)\n\n \n\n26\n\n[Table of Contents](#toc_page)\n\n \n\n \n\n* The material contained in Exhibit 32.1 is not deemed “filed” with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language contained in such filing, except to the extent that the registrant specifically incorporates it by reference.\n\n27\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\nSALARIUS PHARMACEUTICALS, INC.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Frederick E. Pierce\n\n \n\n \n\n \n\n \n\n \n\nFrederick E. Pierce\n\nChief Executive Officer (Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Mark J. Rosenblum\n\n \n\n \n\n \n\n \n\n \n\nMark J. Rosenblum\n\nChief Financial Officer and Executive Vice President of Finance (Principal Financial Officer and Principal Accounting Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\nDate:\n\nMay 8, 2026\n\n \n\n \n\n \n\n \n\n \n\n28"}